We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
-1.7%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$2.53M
Cap. Flow
+$6.01M
Cap. Flow %
3.53%
Top 10 Hldgs %
52.61%
Holding
53
New
12
Increased
19
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
STRM
Streamline Health Solutions
STRM
+$7.38M
2
ALKS icon
Alkermes
ALKS
+$5.2M
3
CVS icon
CVS Health
CVS
+$4.95M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.65M
5
COLL icon
Collegium Pharmaceutical
COLL
+$3.53M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$12.1M
2
UTHR icon
United Therapeutics
UTHR
+$7.07M
3
LH icon
Labcorp
LH
+$5.86M
4
AMGN icon
Amgen
AMGN
+$5.84M
5
MRK icon
Merck
MRK
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.1%
2 Consumer Staples 2.06%
3 Technology 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXGN
51
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-60,000
Closed -$1.05M
TRLV
52
Trulieve Cannabis Corp
TRLV
$1.66B
– –
-7,500
Closed -$86K
1 2
3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2022 Portfolio in Review

As of Q3 2022, Tamarack Advisers held 53 positions worth $170M, down 1.5% from $173M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Tamarack Advisers deployed $6.01M of net new capital in Q3 2022, opening 12 new positions and adding to 19 existing holdings. Its largest new stake was Streamline Health Solutions: 328,725 shares worth $5.87M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Cigna, an estimated $12.1M trimmed.

  • Tamarack Advisers's largest Q3 2022 buy was Streamline Health Solutions: 328,725 shares worth $5.87M.
  • Tamarack Advisers added most to BioMarin Pharmaceuticals in Q3 2022, an estimated $3.65M increase.
  • Tamarack Advisers's biggest Q3 2022 reduction was Cigna, cutting an estimated $12.1M.
  • Tamarack Advisers fully exited United Therapeutics in Q3 2022, selling an estimated $7.07M.
  • Tamarack Advisers's ten largest holdings make up 53% of its $170M portfolio in Q3 2022.
  • Tamarack Advisers opened 12 new positions and closed 7 in Q3 2022.
  • Tamarack Advisers's portfolio value fell 1.5% quarter-over-quarter to $170M.

Based on Tamarack Advisers's 13F filing for Q3 2022, filed 15 Nov 2022.